This study is designed to try to develop better treatments for Acute Myeloid Leukemia (AML) and may help researchers learn more about how to prevent, find, and treat leukemia, other cancers, and other diseases. The primary goal of this trial is to identify genetic abnormalities in leukemia in order to develop new treatments for AML that may work better and/or be less toxic than standard therapy. In addition, we are trying to understand the impact of AML going into deep remission (i.e. not being detectable with any test) has on how long people live.

This phase 1b/2a open-label study will assess the safety, tolerability, pharmacokinetics (what your body does to the drug) and pharmacodynamics (what the drug does to your body) of DISC-0974 as well as categorize the effects on anemia response in subjects with myelofibrosis and anemia.

The purpose of this study is to learn about the safety and recommended dose of the study drug, ZE46-0134 for patients with FLT3 mutated Acute Myeloid Leukemia (AML) after other standard therapies for AML have stopped working or if the approved medications are not appropriate for your treatment.

The purpose of this study is to learn about the safety and recommended dose of the study drug, SNDX-5613 in combination with standard of care treatment – Azacitidine and Venetoclax, for newly diagnosed, untreated AML patients who are over 60, and are not able or do not wish to receive intensive therapy.